The efficacy and safety of telaprevir-based triple therapy in elderly patients with HCV genotype 1 chronic hepatitis C, in comparison with the younger patients

The efficacy and safety of telaprevir-based triple therapy in elderly patients with HCV genotype 1 chronic hepatitis C, in comparison with the younger patients - The efficacy and safety of telaprevir-based triple therapy in elderly patients with HCV genotype 1 chronic hepatitis C, in comparison with the younger patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009711

Enrollment

400

Registered

2013-01-07

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients with HCV genotype 1 chronic hepatitis C

Exclusion criteria

Exclusion criteria: Exclusion criteria were: (1) positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen; (2) clinical or biochemical evidence of hepatic decompensation (ascites, bleeding varices, or encephalopathy); (3) other causes of liver disease (autoimmune hepatitis, primary biliary cirrhosis, or steatohepatitis); (4) excessive active alcohol consumption (a daily intake of more than 40 g of ethanol) or drug abuse; (5) suspected HCC at entry; or (6) treatment with antiviral or immunosuppressive agents prior to enrollment.

Design outcomes

Primary

Measure	Time frame
TVR-based triple therapy can be used successfully and safely to treat elderly patients with genotype 1 chronic hepatitis C.	—

Countries

Japan

Contacts

Public ContactNorihiro Furusyo

Kyushu University Hospital Department of General Internal Medicine

092-642-5909

Outcome results